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The genetic evolution of skin squamous cell carcinoma: tumor 
suppressor identity matters
Caterina Missero
Cutaneous squamous cell carcinoma (cSCC) is the second most com-
mon human malignancy, often arising from the progression of benign 
lesions called actinic keratosis (AK). The progression from AK to cSCC 
is likely a multistep process involving sequential DNA mutations in 
oncogenes and tumor suppressor genes, leading to increased genomic 
instability and/or loss of cell cycle control. Some driver mutations 
involved in human cSCC have been identified, although the patho-
genesis of cSCC at the molecular and genetic level remains largely 
unknown.
The tumor suppressor gene Tp53 is very frequently mutated 
in cSCC, ranging from 44% in a cohort of about 800 patients with 
cSCC (http://cancer.sanger.ac.uk/cosmic) to 79% in advanced cSCC; 
http://www.cbioportal.org/index.do) (Fig. 1).1 Similarly, NOTCH1 and 
NOTCH2 are often mutated in cSCC (Fig. 1).2 In contrast to other tis-
sues in which NOTCH signalling is crucial for stemness and favours 
tumor formation, in the epidermis NOTCH promotes epidermal differ-
entiation, thereby inhibiting skin tumorigenesis (reviewed in3).
Other tumor suppressor genes such as CDKN2A and KMT2D 
are also mutated with a similar frequency (Fig. 1). KMT2D is a 
histone lysine methyltransferase frequently mutated in oesopha-
geal squamous cell cancer, in breast fibroepithelial tumors and in 
lymphoma.4–7 While KMT2D acts as bona fide tumor suppressor 
in lymphomas,8,9 future studies are required to determine its role 
in skin tumorigenesis. Other well- characterized tumor suppressor 
genes, such Rb1 and Pten, are also mutated in cSCC, albeit at a lower 
 frequency (Fig. 1).
Among the genes carrying activating mutations in cSCCs are mem-
bers of the RAS family, HRAS and KRAS (Fig. 1). While the mutation 
frequency for each of these genes is low, their combined mutation 
frequency is more than 10%. In addition, other components of the 
RAS signalling pathway, such as the epidermal growth factor receptor 
(EGFR) and the effector BRAF, are also mutated in cSCCs at a low 
 frequency (Fig. 1).
Cutaneous squamous cell carcinomas have been extensively stud-
ied in mouse models using a chemical carcinogenesis protocol, causing 
mutations in either HRAS in 67% of the tumors or, less frequently, in 
KRAS (19%).10 Most genetic models that have been studied to date 
take advantage of inducible mutations in KRAS in combination with 
other oncogenes or tumor suppressor genes.11–13
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F IGURE  1 More frequently mutated genes in advanced 
Cutaneous squamous cell carcinoma (cSCC). Targeted sequencing 
of 504 cancer- associated genes on lymph node metastases in 29 
patients with cSCC23–25
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One important, unanswered question in skin tumor biology is 
whether the severity of the tumor is related to the different underlying 
mutations, cell of origin or variable genomic instability.
To dissect this question, in a recently published issue of Experimen-
tal Dermatology, Flores et al. test the hypothesis that a specific popula-
tion of cells within the epidermis has the capability to generate differ-
ent types of tumors depending on the tumor suppressor gene that is 
deleted. To this purpose, they generated three mouse models in which 
an activating KRAS mutation was accompanied by concomitant deletion 
of genes encoding distinct tumor suppressor genes (Trp53, Pten or Rb1) 
in the hair follicle stem cell compartment (HFSC).14 An extensive patho-
logical examination was performed to analyse the resulting phenotypes 
in detail. The HFSC was chosen because its composition is relatively 
homogenous, being localized in the hair follicle bulge, and can be specif-
ically targeted by Cre recombinase with a keratin 15 promoter. Previous 
studies have shown that both interfollicular epidermis and the HFSC and 
their immediate progeny are competent to generate cSCCs.12,15
In this context, KRAS- activating mutations coupled with p53 
deletion led to aggressive SCC, including high- grade spindle cell 
SCC as previously described.11–13 In contrast, KRAS activation cou-
pled with Rb1 deletion led to benign papillomas, and hypertrophy of 
the infundibulum and sebaceous glands. Similarly, KRAS activation 
coupled with Pten deletion caused squamous hyperplasia eventu-
ally leading to papillomas or keratoacanthomas, and benign tumors 
of the skin characterized by rapid growth and spontaneous regres-
sion.16 This study is in agreement with the observation that Tp53 is 
mutated in a high percentage of human cSCCs, whereas Pten and 
Rb1 are infrequently mutated. Therefore, the main finding of the 
present work is that a specific subset of epidermal stem cells can 
give rise to a variety of tumorigenic phenotypes depending on the 
tumor suppressor that is deleted, and that the identity of the tumor 
suppressor lost in the process of carcinogenesis determines the 
phenotype of the tumor.14
This study by Flores and colleagues should inspire future research 
to further address the roles of other oncogenes and tumor suppres-
sors in cSCC formation, in particular those that are more frequently 
mutated in cSCCs, such as NOTCH1, NOTCH2, CDKN2A and KMTD2. 
An important emerging question in cSCC research is whether the 
order in which mutations of oncogenes and tumor suppressors occur 
is relevant for the severity of the disease. For instance, ultraviolet 
(UV)- induced mutations in Tp53 may often be an early event since 
these mutations are found in normal- appearing skin (reviewed in1). In 
addition, the influence of overexpression of regulatory genes such as 
TP631,17 and SOX218–20 will have to be further studied in cSCC. Future 
experiments could make use of recently developed technologies that 
take advantage of intra- vital imaging21 to study early stages of the 
precursor lesions and to follow the fate of tumorigenic cells in real 
time when different tumor suppressors are lost.
Another interesting point that will need to be addressed in the 
future is how the combination of mutations or deletions of several 
genes may influence each other. Genome editing techniques, such as 
the CRISPR/CAS9 technology that enables concomitant or sequen-
tial genomic mutations,22 will allow rapid development of models 
bearing combinations of mutations or deletions of multiple genes 
simultaneously.
In conclusion, the present work sets the basis for more sophisti-
cated studies aimed at modelling cSCC in mice to identify innovative 
therapeutic targets for treating this cancer.
CONFLICT OF INTERESTS
The authors have declared no conflicting interests.
REFERENCES
 1. Missero C, Antonini D. Exp Dermatol. 2014;23:143–146.
 2. Wang NJ, Sanborn Z, Arnett KL, et al. Proc Natl Acad Sci USA. 
2011;108:17761–17766.
 3. Dotto GP. Nat Rev Cancer. 2009;9:587–595.
 4. Lin DC, Hao JJ, Nagata Y, et al. Nat Genet. 2014;46:467–473.
 5. Okosun J, Bodor C, Wang J, et al. Nat Genet. 2014;46:176–181.
 6. Song Y, Li L, Ou Y, et al. Nature. 2014;509:91–95.
 7. Tan J, Ong CK, Lim WK, et al. Nat Genet. 2015;47:1341–1345.
 8. Ortega-Molina A, Boss IW, Canela A, et al. Nat Med. 2015;21:1199–
1208.
 9. Zhang J, Dominguez-Sola D, Hussein S, et al. Nat Med. 2015;21:1190–
1198.
10. Nassar D, Latil M, Boeckx B, et al. Nat Med. 2015;21:946–954.
11. Caulin C, Nguyen T, Lang GA, et al. J Clin Investig. 2007;117:1893–
1901.
12. Lapouge G, Youssef KK, Vokaer B, et al. Proc Natl Acad Sci USA. 
2011;108:7431–7436.
13. White AC, Tran K, Khuu J, et al. Proc Natl Acad Sci USA. 2011;108:7425–
7430.
14. Flores AGW, White AC, Scumpia P, Takahashi R, Lowry WE. Exp 
 Dermatol. 2016;25:733–735.
15. Blanpain C. Nat Cell Biol. 2013;15:126–134.
16. Gleich T, Chiticariu E, Huber M, et al. Exp Dermatol. 2016;25:85–91.
17. Romano RA, Sinha S. Exp Dermatol. 2014;23:238–239.
18. Boumahdi S, Driessens G, Lapouge G, et al. Nature. 2014;511:246–
250.
19. Chen Y, Sen GL. Exp Dermatol. 2015;24:974–976.
20. Siegle JM, Basin A, Sastre-Perona A, et al. Nat Commun. 2014;5:4511.
21. Brown S, Greco V. Cell Stem Cell. 2014;15:683–686.
22. Platt RJ, Chen S, Zhou Y, et al. Cell. 2014;159:440–455.
23. Gao J, Aksoy BA, Dogrusoz U, et al. Sci Signal. 2013;6:pl1.
24. Cerami E, Gao J, Dogrusoz U, et al. Cancer Discov. 2012;2:401–404.
25. Li YY, Hanna GJ, Laga AC, et al. Clin Cancer Res. 2015;21:1447–1456.
